These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25935642)

  • 1. Discovery of novel N-aryl piperazine CXCR4 antagonists.
    Zhao H; Prosser AR; Liotta DC; Wilson LJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4950-4955. PubMed ID: 25935642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
    Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
    McCauley JP; Dantzman CL; King MM; Ernst GE; Wang X; Brush K; Palmer WE; Frietze W; Andisik DW; Hoesch V; Doring K; Hulsizer J; Bui KH; Liu J; Hudzik TJ; Wesolowski SS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1169-73. PubMed ID: 22197139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zwitterionic CRTh2 antagonists.
    Luker T; Bonnert R; Paine SW; Schmidt J; Sargent C; Cook AR; Cook A; Gardiner P; Hill S; Weyman-Jones C; Patel A; Thom S; Thorne P
    J Med Chem; 2011 Mar; 54(6):1779-88. PubMed ID: 21355602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
    Yun J; Han M; Song C; Cheon SH; Choi K; Hahn HG
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3234-7. PubMed ID: 24974340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers.
    Choi YH; Baek du J; Seo SH; Lee JK; Pae AN; Cho YS; Min SJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):215-9. PubMed ID: 21126876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Markotan T; Lanter J; Cai C; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5577-82. PubMed ID: 21783361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
    Procopiou PA; Ancliff RA; Bamford MJ; Browning C; Connor H; Davies S; Fogden YC; Hodgson ST; Holmes DS; Looker BE; Morriss KM; Parr CA; Pickup EA; Sehmi SS; White GV; Watts CJ; Wilson DM; Woodrow MD
    J Med Chem; 2007 Dec; 50(26):6706-17. PubMed ID: 18052318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
    Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
    Butini S; Campiani G; Franceschini S; Trotta F; Kumar V; Guarino E; Borrelli G; Fiorini I; Novellino E; Fattorusso C; Persico M; Orteca N; Sandager-Nielsen K; Jacobsen TA; Madsen K; Scheel-Kruger J; Gemma S
    J Med Chem; 2010 Jun; 53(12):4803-7. PubMed ID: 20481570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
    Fox BM; Natero R; Richard K; Connors R; Roveto PM; Beckmann H; Haller K; Golde J; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2460-7. PubMed ID: 21414780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
    Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
    J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
    Roughley SD; Browne H; Macias AT; Benwell K; Brooks T; D'Alessandro J; Daniels Z; Dugdale S; Francis G; Gibbons B; Hart T; Haymes T; Kennett G; Lightowler S; Matassova N; Mansell H; Merrett A; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Simmonite H; Tan K; Walls SB; Wong M
    Bioorg Med Chem Lett; 2012 Jan; 22(2):901-6. PubMed ID: 22209458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
    Pajouhesh H; Feng ZP; Zhang L; Pajouhesh H; Jiang X; Hendricson A; Dong H; Tringham E; Ding Y; Vanderah TW; Porreca F; Belardetti F; Zamponi GW; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4153-8. PubMed ID: 22579422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.
    Dey D; Chaskar S; Athavale N; Chitre D
    Biomed Res Int; 2015; 2015():971982. PubMed ID: 25893199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.
    Truax VM; Zhao H; Katzman BM; Prosser AR; Alcaraz AA; Saindane MT; Howard RB; Culver D; Arrendale RF; Gruddanti PR; Evers TJ; Natchus MG; Snyder JP; Liotta DC; Wilson LJ
    ACS Med Chem Lett; 2013 Nov; 4(11):1025-30. PubMed ID: 24936240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
    Nugiel DA; Krumrine JR; Hill DC; Damewood JR; Bernstein PR; Sobotka-Briner CD; Liu J; Zacco A; Pierson ME
    J Med Chem; 2010 Feb; 53(4):1876-80. PubMed ID: 20088516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based development of antagonists for chemokine receptor CXCR4.
    Zhang C; Hou T; Feng Z; Li Y
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
    Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
    Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.
    Iyengar RR; Lynch JK; Mulhern MM; Judd AS; Freeman JC; Gao J; Souers AJ; Zhao G; Wodka D; Doug Falls H; Brodjian S; Dayton BD; Reilly RM; Swanson S; Su Z; Martin RL; Leitza ST; Houseman KA; Diaz G; Collins CA; Sham HL; Kym PR
    Bioorg Med Chem Lett; 2007 Feb; 17(4):874-8. PubMed ID: 17234405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.